Markets
markets
Luke Kawa

Why Nvidia and AMD’s unusual agreement with the Trump administration might survive any legal challenges

There is one glaring issue with the highly unusual arrangement that’s seen Nvidia and Advanced Micro Devices secure export licenses to China for chips that had previously faced restrictions in return for giving the US government 15% of the revenues generated by those sales:

Legal experts say it is of very dubious legality, to put it mildly.

“No matter the substantive merits of that pushback — this and other potential future deals like it are unlikely to be struck down by the courts (and sales and government revenue thereby interrupted) anytime soon,” George Pollack, a senior US policy analyst at Signum Global Research, wrote.

The first reason is the issue of standing, or rather, who can claim to have been hurt by this agreement.

Here are two people with law degrees discussing this very point, and one person who has watched “Law & Order” musing about the potential for this to end up in the courts.

(I would be very amused by Nvidia and/or AMD shareholders arguing that they’ve suffered from management agreeing to the 15% fee and not being able to benefit from what the full sales, not just 85% of them, would mean for those companies’ bottom lines and their potential returns.)

Pollack argues that Nvidia and AMD themselves would be unlikely to pursue a legal battle (given, you know, they agreed to this), and that Congress, trade associations, or the state of California would face difficulties getting a court to see things their way.

Secondly, the analyst flagged that there are two potential technical loopholes the Trump administration could turn to in order to avoid having this deal overturned by the courts:

  1. The chips themselves are physically not produced in the US, so “they do not technically qualify as ‘exports’ in the constitutional sense,” he wrote.

  2. “The 15% revenue share is entered into voluntarily by the companies, it is therefore not a mandated ‘fee’,” he noted.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets
Luke Kawa

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.